HomeThe Column

The Column

5 Billion Yen Blockbuster?

Shinya Sato

What has been billed as a potential multibillion-dollar blockbuster has now hit the Japanese hemophilia market. Despite much hype worldwide, though, the hemophilia A therapy Hemlibra (emicizumab) carries a peak sales forecast of just five billion yen in Japan. Its sales were never expected to be very big in this country alone, but five billion yen seems just too low. Why? I looked at the figures a little closer ...


News Calendar